Pharmamarketeer

Rapastinel Fails to Meet Primary Endpoint in Phase 3 Adjunctive MDD Trials

Clinical studies evaluating the safety, efficacy and tolerability of rapastinel as an adjunctive treatment for major depressive disorder (MDD) did not meet primary and key secondary endpoints, according to topline results announced by Allergan.

Medhc-fases-banner
Advertentie(s)